Global Liquid Biopsy Market Industry Trends and Forecast to 2034: Segmented by (Biomarker, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Global · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$7.61 BnPlaceholder estimate
Estimate 2025$8.90 BnPlaceholder estimate
Projected 2034$36.56 Bn 310.8%Adds $27.66 Bn over 9 forecast years
CAGR 2025–203417.0%Faster than 90% of 173 Medical Devices markets here
291 worldwideSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, worldwide. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Global Liquid Biopsy Market Analysis Executive Summary
Liquid biopsy finds cancer signals such as tumour DNA in a blood sample, to detect cancer, guide treatment and check for relapse.
Key segments of the liquid Biopsy market include biomarker (Circulating Tumor DNA, Circulating Tumor Cells and Exosomes) and application (Treatment Selection, Recurrence Monitoring and Early Detection).
Global Liquid Biopsy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Global Liquid Biopsy Market Dynamics
Market Growth Drivers
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the liquid Biopsy market. Faster approvals and new combinations are improving survival.
Opportunity
Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the liquid Biopsy market.
Market Restraints
High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the liquid Biopsy market, especially in low- and middle-income countries.
Competitive Landscape for Liquid Biopsy Market in Global
The liquid Biopsy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Liquid Biopsy Market in Global
Liquid Biopsy worldwide: rules, payment and research
There is no single global regulator; the International Medical Device Regulators Forum (IMDRF) helps national regulators align their device rules.[1] WHO reports that 4.5 billion people were not fully covered by essential health services in 2021.[2] ClinicalTrials.gov lists 291 studies on Liquid Biopsy that are recruiting, active or about to start worldwide.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, worldwide. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how liquid Biopsy products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Global.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Biomarker
4.2 By Application
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Guardant Health
7.2 Roche (Foundation Medicine)
7.3 GRAIL
7.4 Natera
7.5 Exact Sciences
7.6 Illumina
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The liquid Biopsy market can be segmented based on various criteria, including biomarker, application and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Liquid Biopsy right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Placeholder estimate: about $8.90 Bn in 2025, rising to about $36.56 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Liquid Biopsy market worldwide growing?
Placeholder estimate: about 17.0% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Liquid Biopsy market report cover?
The report splits the market by biomarker (Circulating Tumor DNA, Circulating Tumor Cells, Exosomes), application (Treatment Selection, Recurrence Monitoring, Early Detection) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Liquid Biopsy market?
Key players include Guardant Health, Inc., Roche, GRAIL, Natera, Exact Sciences Corporation and Illumina, Inc..
What is driving the Liquid Biopsy market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the liquid Biopsy market. Faster approvals and new combinations are improving survival.
Who regulates Liquid Biopsy worldwide?
There is no single global regulator; the International Medical Device Regulators Forum (IMDRF) helps national regulators align their device rules. Source: International Medical Device Regulators Forum. Checked 14 Nov 2026.
How many clinical trials on Liquid Biopsy are running worldwide?
291 studies are recruiting, active or about to start worldwide, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, worldwide. Retrieved 12 Nov 2026.
How much research is published on Liquid Biopsy?
PubMed lists 10,752 papers on Liquid Biopsy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
US
India
China
Canada
Japan
Germany
UK
France
Brazil
Spain
Ecuador
Italy
Saudi Arabia
Mexico
Russia
Australia
New Zealand
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Singapore
Thailand
Kenya